Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 11:32 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1369–1392 of 3,925 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: HTN Clear all

Conditions: Interstitial Lung Disease, COPD, Pulmonary Arterial Hypertension
Interventions: Hyperpolarized 129Xe; Drug
Lead sponsor: Bastiaan Driehuys; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Normal Tension Glaucoma, Obstructive Sleep Apnea
Interventions: Clinical observation, diagnostic testing; Other
Lead sponsor: Northwell Health; Other
Eligibility: 21 Years and older
Enrollment: 100 participants
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: New York, New York

Conditions: Primary Open Angle Glaucoma
Interventions: Not listed
Lead sponsor: Glaukos Corporation; Industry
Eligibility: Not listed
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 26
States / cities: Beverly Hills, California • Petaluma, California • Sacramento, California + 23 more

Conditions: Hypertension
Interventions: self-management protocol for hypertension care; Other
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 232 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 2
States / cities: San Diego, California • San Francisco, California

Conditions: Primary Open-Angle Glaucoma (POAG), Ocular Hypertension (OHT)
Interventions: trabodenoson 4.5% BID, trabodenoson 6.0% QD, trabodenoson 3.0% QD, timolol 0.5% BID, placebo BID; Drug
Lead sponsor: Inotek Pharmaceuticals Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 303 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Lexington, Massachusetts

Conditions: Fuchs Endothelial Corneal Dysfunction, Open Angle Glaucoma (OAG), Dry Eye Disease (DED), Keratoconus, Lasik Eye Surgery
Interventions: Not listed
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 20 Years to 79 Years
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hypertension, Pulmonary
Interventions: GSK2586881; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 2
States / cities: Pittsburgh, Pennsylvania • Dallas, Texas

Conditions: Ocular Hypertension, Open-Angle Glaucoma
Interventions: Latanoprost Punctal Plug Delivery System (L-PPDS); Drug
Lead sponsor: Mati Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 18
States / cities: Chandler, Arizona • Phoenix, Arizona • Torrance, California + 15 more

Conditions: Primary Open Angle Glaucoma (POAG), Ocular Hypertension (OHT)
Interventions: REGN22530; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 271 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Deerfield Beach, Florida

Conditions: Glaucoma
Interventions: Ranibizumab; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 21 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Hypertension in Pregnancy, Gestational Hypertension, Preeclampsia, Chronic Hypertension With Pre-Eclampsia, Eclampsia, Chronic Hypertension in Obstetric Context
Interventions: virtual cardiac wellness program, Placebo comparator; Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older · Female only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hypertension
Interventions: Self-Measured Blood Pressure Monitoring, Physician appointment and transportation scheduling; Behavioral
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 99 Years
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Flint, Michigan

Conditions: Lung Transplant, Pulmonary Hypertension
Interventions: Protek Solo Transseptal Cannula; Device
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 80 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Primary Open Angle Glaucoma, Glaucoma, Primary Open Angle Glaucoma or Ocular Hypertension
Interventions: Direct Selective Laser Trabuloplasty; Device
Lead sponsor: Brian Shafer; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2026
U.S. locations: 1
States / cities: Plymouth Meeting, Pennsylvania

Conditions: Open-Angle Glaucoma, Ocular Hypertension
Interventions: Bimatoprost SR, Standard of Care; Drug · Other
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 455 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 66
States / cities: Dothan, Alabama • Chandler, Arizona • Phoenix, Arizona + 60 more

Conditions: Aniridia, Eye Abnormality, Ocular Hypertension, Open Angle Glaucoma
Interventions: Not listed
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: Not listed
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1977 – 2002
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Glaucoma
Interventions: Travoprost 0.004%/timolol maleate 0.5% fixed combination; Drug
Lead sponsor: Alcon Research; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Fort Worth, Texas

Conditions: Glaucoma, Ocular Hypertension (OH)
Interventions: Latanoprost-PPDS; Drug
Lead sponsor: Mati Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 6
States / cities: Artesia, California • Los Angeles, California • San Diego, California + 3 more

Conditions: Hypertension
Interventions: Electro-acupuncture control, Electro-acupuncture test; Procedure
Lead sponsor: University of California, Irvine; Other
Eligibility: 18 Years to 85 Years
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2027
U.S. locations: 2
States / cities: Irvine, California • Orange, California

Conditions: Diabetes, Hypertension, High Cholesterol/Hyperlipidemia, Coronary Artery Disease, Congestive Heart Failure, Chronic Lung Disease, Chronic Kidney Diseases, Arrythmia, Stroke, Depression, Anxiety, Pulmonary Embolism, Heart Attack
Interventions: Med AAAction intervention; Other
Lead sponsor: University of Tennessee; Other
Eligibility: 18 Years and older
Enrollment: 388 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 2
States / cities: Knoxville, Tennessee • Memphis, Tennessee

Conditions: Hypertension, Pulmonary
Interventions: Riociguat (Adempas, BAY63-2521); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 58
States / cities: Tucson, Arizona • La Jolla, California • Moreno Valley, California + 51 more

Conditions: Hypertension
Interventions: Nebivolol; Drug
Lead sponsor: Mylan Bertek Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2003
U.S. locations: 1
States / cities: Morgantown, West Virginia

Conditions: Subclinical Hypercortisolism, Cushing Syndrome, Adrenal Neoplasm
Interventions: Adrenalectomy, Observation; Procedure · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Glaucoma
Interventions: Personalized Glaucoma Coaching, Enhanced Standard care; Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 236 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 2
States / cities: Ann Arbor, Michigan • Detroit, Michigan

Search by objective public record fields.

Pulmonary Hypertension SOLAR

Obstructive Sleep Apnea as a Risk Factor for Normal Tension Glaucoma and a Crucial Step in Preventing Blindness

Post-approval Study of The Glaukos® iStent® Trabecular Micro-bypass Stent: Extended Follow-up of the Premarket Cohort

Self-management of Blood Pressure Medication for Hypertensive Veterans

Study of Trabodenoson in Adults With Ocular Hypertension or Primary Open-angle Glaucoma

A Study to Assess Brillouin Hydration Mapping for the Evaluation of Ocular Tissues and Diseases

A Dose-escalation Study in Subjects With Pulmonary Arterial Hypertension (PAH)

A Phase 2 Single-Masked, Randomized Study of Latanoprost PPDS in Ocular Hypertension or Open-Angle Glaucoma

REGN22530 for Adults With Primary Open Angle Glaucoma or Ocular Hypertension

Ranibizumab in Preventing Failure of Ahmed Valve Glaucoma Surgery

Virtual Cardiac Wellness Program Following Hypertensive Disorders of Pregnancy

Reach Out 2: Emergency Department-Initiated Hypertension Mobile Health Intervention Connecting Multiple Health Systems

Bridge to Lung Transplant With Trans-septal Extra-corporeal Membrane Oxygenation (ECMO) for Right Heart Failure From Pulmonary Hypertension

A Prospective Study on the Efficacy of Direct Selective Laser Trabeculoplasty (DSLT) in Achieving >20% Intraocular Pressure (IOP) Reduction Without Medications at 6 Months in Naive, Untreated Glaucoma Patients

Long-term Safety and Efficacy Extension Trial of Bimatoprost SR

Abnormalities of the Eye's Anterior Chamber, Iris, Cornea and Lens

Safety and Efficacy of Changing to DuoTrav in Patients Uncontrolled on Timolol

A Dose Evaluation Study for the Latanoprost Punctal Plug Delivery System (L-PPDS) in Subjects With Ocular Hypertension or Open-Angle Glaucoma

Effect of Electro-Acupuncture on Blood Pressure

Pharmacy-led Transitions of Care Intervention to Improve Medication Adherence

Measuring Outcomes In Patients With Pulmonary Arterial Hypertension Not on Active Treatment (MOTION)

A Study of the Safety and Efficacy of Nebivolol in Hypertensive Patients

Study of Adrenalectomy Versus Observation for Subclinical Hypercortisolism

The Support, Educate, Empower (SEE) Program